September 14th, 2005
Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (NASDAQ:
ALKS) reported that a Phase 2 clinical study of inhaled insulin for those with type 1 diabetes indicated that blood sugar
levels for inhaled insulin were similar to those for injected insulin. According to the announcement, “Using the standard
measure of blood sugar, A1C, patients achieved an average level of 7.9 using the Lilly/Alkermes inhaled insulin system, compared
to 8.0 in the injected insulin group. A1C is an average measure of blood sugar (glucose) over a three-month period.”
The study revolved around the Lilly/Alkermes system. The results
of findings were presented at the 41st annual meeting of the European Association for the Study of Diabetes in Athens, Greece.